Polyclonal antibody stimulator - Cancer Advances

Drug Profile

Polyclonal antibody stimulator - Cancer Advances

Alternative Names: Anti-gastrin 17 immunogen; G17DT; Gastrimmune; Insegia; PAS

Latest Information Update: 11 Sep 2015

Price : $50

At a glance

  • Originator Aphton Corporation
  • Developer Cancer Advances
  • Class Antiulcers; Cancer vaccines; Peptide hormones
  • Mechanism of Action Gastrin 17 inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Gastric cancer; Pancreatic cancer
  • Phase II Colorectal cancer; Gastro-oesophageal reflux

Most Recent Events

  • 11 May 2015 The product is in phase-III development for Gastric cancer and phase-II for Gastro-oesophageal reflux in USA, and phase-II for Colorectal cancer in USA and Europe
  • 03 Feb 2011 Polyclonal antibody stimulator - Cancer Advances is still available for licensing as of 01 Jan 2011.
  • 03 Feb 2010 Efficacy data from a clinical studies in Colorectal cancer presented at the 12th World Congress on Gastrointestinal Cancer (ESMO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top